CAJ | 학술논문

目的观察不同浓度他莫昔芬软膏对兔耳增生性瘢痕成纤维细胞和转化生长因子的影响,并探讨其防治增生性瘢痕的可行性.方法采用兔耳增生性瘢痕模型,将96只新西兰长耳兔共576个耳创面随机分为实验A、B、C组和对照组D组,每组创面144个,实验A、B、C组分别外涂不同浓度(0.5%,1%,2%)的他莫昔芬软膏,D组则涂以空白软膏,分别于术后30、60、90 d切取增生的瘢痕组织,测量瘢痕厚度、观察瘢痕组织形态学变化,并检测成纤维细胞密度及瘢痕组织中TGFβ2 含量变化.结果 ①30 d时,A、D组与B、C组瘢痕厚度差异有统计学意义(P＜0.05),A、D组＜B组＜C组;成纤维细胞密度与TGF-β2 含量则相反,A、D组＞B组＞C组(P＜0.05).② 60、90 d时,4组瘢痕厚度、成纤维细胞密度及TGF-β2 含量差异有统计学意义(P＜0.05),A、B、C、D组TGF-β2含量60 d时分别为:(43.97±3.63)μg/L、(41.92±3.91)μg/L、(36.69±4.15)μg/L、(54.90±4.71)μg/L,90 d时分别为:(45.69 ±2.63)μg//L、(40.43±3.87)μg/L、(38.76±3.24)μg//L、(52.59±4.92)μg/L;成纤维细胞密度60 d时A、B、C、D组分别为:(4 392.07±327.84)个/mm2、(4 208.57±329.76)个/mm2、(4 033.44±427.91)个/mm2、(4 863.03±387.98)个/mm2,90 d时分别为:(4 418.41 ±432.52)个/mm2、(4 077.65 ±386.70)个/mm2、(3 844.53 ±354.29)个/mm2、(4 838.64±390.52)个/mm2,D组＞A组＞B组＞C组(P＜0.05).结论外用他莫昔芬可降低TGF-β2,减少成纤维细胞数目,引起瘢痕萎缩,从而防治瘢痕增生.
목적 관찰불동농도타막석분연고대토이증생성반흔성섬유세포화전화생장인자적영향,병탐토기방치증생성반흔적가행성.방법 채용토이증생성반흔모형,장96지신서란장이토공576개이창면수궤분위실험A、B、C조화대조조D조,매조창면144개,실험A、B、C조분별외도불동농도(0.5%,1%,2%)적타막석분연고,D조칙도이공백연고,분별우술후30、60、90 d절취증생적반흔조직,측량반흔후도、관찰반흔조직형태학변화,병검측성섬유세포밀도급반흔조직중TGFβ2 함량변화.결과 ①30 d시,A、D조여B、C조반흔후도차이유통계학의의(P＜0.05),A、D조＜B조＜C조;성섬유세포밀도여TGF-β2 함량칙상반,A、D조＞B조＞C조(P＜0.05).② 60、90 d시,4조반흔후도、성섬유세포밀도급TGF-β2 함량차이유통계학의의(P＜0.05),A、B、C、D조TGF-β2함량60 d시분별위:(43.97±3.63)μg/L、(41.92±3.91)μg/L、(36.69±4.15)μg/L、(54.90±4.71)μg/L,90 d시분별위:(45.69 ±2.63)μg//L、(40.43±3.87)μg/L、(38.76±3.24)μg//L、(52.59±4.92)μg/L;성섬유세포밀도60 d시A、B、C、D조분별위:(4 392.07±327.84)개/mm2、(4 208.57±329.76)개/mm2、(4 033.44±427.91)개/mm2、(4 863.03±387.98)개/mm2,90 d시분별위:(4 418.41 ±432.52)개/mm2、(4 077.65 ±386.70)개/mm2、(3 844.53 ±354.29)개/mm2、(4 838.64±390.52)개/mm2,D조＞A조＞B조＞C조(P＜0.05).결론 외용타막석분가강저TGF-β2,감소성섬유세포수목,인기반흔위축,종이방치반흔증생.
Objective To observe the effect of different concentration of Tamoxifen ointment on the fibroblasts and transforming growth factor (TGF-β2) of hypertrophic scar at rabbit ears, so as to explore the possibility of treatment of hypertrophic scar with Tamoxifen. Methods The hypertrophic scar model was established in 96 New Zealand rabbits' ears. The wounds were divided into four groups (A, B, C and D) , with 144 wounds in each group. Different concentration of tamoxifen ointment(0. 5% ,1% ,2% ) was topically administered in groups A, B and C respectively, and blank ointment in group D. On postoperative (54. 90 ±4. 71) μg/L, respectively, on 60th day; and (45. 69 ±2.63) μg/L, (40. 43 ±3.87) μg/L, (38. 76 ±3. 24) μg/L, (52. 59 ±4. 92) μg/L, respectively, on 90th day. The fibroblasts density of scar in groups A, B, C, D was (4 392. 07 ± 327. 84 ) point/mm2, ( 4 208. 57 ± 329. 76 ) point/mm2, (4 033.44 ±427.91) point/mm2, (4 863.03 ±387.98) point/mm2, respectively, on 60 th day; and (4 418. 41 ±432. 52) point/mm2, (4 077. 65 ±386. 70) point/mm2, (3 844. 53 ±354. 29) point/mm2,(4 838.64 ±390.52) point/mm2, respectively, on 90th day. The content of TGF-β2 and fibroblasts density of scar were lined up as group D ＞ group A ＞ group B ＞ group C ( P ＜ 0. 05 ) . Conclusions Topical Tamoxifen'can reduce the content of TGF-β2 and fibroblast, decrease fibroblasts density and the formation of hypertrophic scar at rabbit ears. It offers a new way for the treatment of the hypertrophic scar.